A sterile and reliable alternative for cancellous autograft or allograft. It is biocompatible and osteoconductive. The composition of ELIZ ( 60% HA and 40% b-TCP ) is similar to the mineral component of human bone and undergoes complete resorption at controlled rate. Due to the similarity of the interconnected structure with human cancellous bone, ELIZ provides and ideal enviroment for the ingrowth of new bone.

1. 11

2. 2

3. 11
Table of Contents :
Section 1 ELIZ Product 2
Description 2
Ordering Information 3
Section 2 OSIQ Product 4
Description 4
Ordering information 5
Section 3 ZETH Product 6
Description 6-7
Ordering information 7

4. 22
ELIZ is a sterile and reliable alternative for cancellous autograft or allograft. It is biocompatible and osteoconduc-
tive. The composition of ELIZ (60% HA and 40% b-TCP) is similar to the mineral component of human bone and
undergoes complete resorption at a controlled rate. Due to the similarity of the interconnected structure with human
cancellous bone, ELIZ provides an ideal environment for the ingrowth of new bone.
The porosity of ELIZ is 83%. This ultra high porosity allows rapid bone ingrowth throughout the pores. ELIZ will
provide support without significantly limiting natural bone density. Microporosity (1.0 – 10um) within the HA/TCP
structure assists the transfer of essential nutrients.
ELIZ bone graft substitute
A safe and effective substitute for autograft
ELIZ is gamma sterilized and available is several
volumes and sizes. Supported by more than 3000
publications and over 500 clinical studies with respect to
the biocompatibility and clinical efficacy of HA and b-TCP
as bone substitute material, 25 years of successful use
is proven.
FEATURES
- Proven biocompatibility and osteoconductivity
- Osteoblastic activity is encourages by osteoclastic resorp-
tion and phagocytosis, releasing calcium and phosphate ions
locally
- For easy handling, ELIZ granules can be mixed with
blood, bone marrow or platelet concentrate to form a cohe-
sive mixture
- ELIZ will integrate with new bon completely within 12 - 14
weeks. The implant is than embedded within new bone form-
ing bicontinuous matrix
Ordering Information
Type Volume Packaging Art. code EAN bar code
Strip 4 x 10 x 45 mm Box of 1 unit 4912311 8718026120xxx
4 x 10 x 45 mm Box of 3 units 4912310 8718026120474
5 x 12 x 50 mm Box of 1 unit 4912321 8718026120xxx
5 x 12 x 50 mm Box of 3 units 4912320 8718026120481

5. 33
Type Volume Packaging Art. code EAN bar code
Cylinder 5D x 5mm Box of 1 unit 4912110 8718026120214
5D x 10 mm Box of 1 unit 4912111 8718026120221
10D x 10 mm Box of 1 unit 4912121 8718026120245
10D x 15 mm Box of 1 unit 4912122 8718026120252
15D x 15 mm Box of 1 unit 4912132 8718026120283
15D x 20 mm Box of 1 unit 4912133 8718026120290
20D x 20 mm Box of 1 unit 4912143 8718026120337
Type Volume Packaging Art. code EAN bar code
Block 5 x 10 x 10 mm Box of 1 unit 4912410 8718026120344
5 x 10 x 20 mm Box of 1 unit 4912412 8718026120351
10 x 10 x 10 mm Box of 1 unit 4912420 8718026120382
10 x 20 x 20 mm Box of 1 unit 4912460 8718026120429
10 x 20 x 40 mm Box of 1 unit 4912480 8718026120443
20 x 20 x 20 mm Box of 1 unit 4912492 8718026120467
Type Volume Packaging Art. code EAN bar code
Granules 0.8 - 1.5 mm 0.25 cc Box of 1 unit 4915002 8718026121747
0.5 cc Box of 1 unit 4915005 8718026121754
1.0 cc Box of 1 unit 4915010 8718026121761
1.5 cc Box of 1 unit 4915015 8718026121778
2.0 cc Box of 1 unit 4915020 8718026121785
2.5 cc Box of 1 unit 4915025 8718026120146
5.0 cc Box of 1 unit 4915050 8718026120153
10.0 cc Box of 1 unit 4915100 8718026120160
15.0 cc Box of 1 unit 4915150 8718026120177
20.0 cc Box of 1 unit 4915200 8718026120184
25.0 cc Box of 1 unit 4915250 8718026120191
30.0 cc Box of 1 unit 4915300 8718026120207
Type Volume Packaging Art. code EAN bar code
Granules 1.0 - 4.0 mm 2.5 cc Box of 1 unit 4911025 8718026120009
5.0 cc Box of 1 unit 4911050 8718026120016
10.0 cc Box of 1 unit 4911100 8718026120023
15.0 cc Box of 1 unit 4911150 8718026120030
20.0 cc Box of 1 unit 4911200 8718026120047
25.0 cc Box of 1 unit 4911250 8718026120054
30.0 cc Box of 1 unit 4911300 8718026120061
Type Volume Packaging Art. code EAN bar code
Granules 0.5 - 1.0 mm 0.25 cc Box of 1 unit 4914002 8718026121693
0.5 cc Box of 1 unit 4914005 8718026121709
1.0 cc Box of 1 unit 4914010 8718026121716
1.5 cc Box of 1 unit 4914015 8718026121723
2.0 cc Box of 1 unit 4914020 8718026121730
2.5 cc Box of 1 unit 4914025 8718026120078
5.0 cc Box of 1 unit 4914050 8718026120085
10.0 cc Box of 1 unit 4914100 8718026120092
15.0 cc Box of 1 unit 4914150 8718026120108
20.0 cc Box of 1 unit 4914200 8718026120115
25.0 cc Box of 1 unit 4914250 8718026120122
30.0 cc Box of 1 unit 4914300 8718026120139

6. 44
OSIQ is a ready-to-use nano bone graft substitute which is an
injectable bone matrix paste.It is fully synthetic ultra pure nano
hydroxyapatite which can be used for the filling or reconstruc-
tion of small and medium bone defects. OSIQ can be combined
with ELIZgranules, REOS strips, or autologous and allogenic
cancellous bone likeZETH. OSIQ does not harden in contact
with blood or spongiosa. OSIQ is non-load-bearing and is due
to its nanocrystalline structure degradable. The unique viscosity
of OSIQ will not harden, this will ensure a quick resorption by
macrophages and osteoclasts.
SYNTHETIC bone substitute
Synthetic bone substitute of pure nano hydroxyapatite
FEATURES
- Innovative nano technology
- Ready to use injectable
- Fully synthetic
- Biodegradable
INDICATIONS
- Osteotomies
- Filling cages in spinal surgery
- Defect filling - small / medium
- Acetabulum reconstruction
- Metaphysial fractures
BIOCOMPATIBILITY
During in vitro test to investigate the biocompatibility of OSIQ it was compared with another commercial aviail-
able nano-paste. OSIQ showed evidence of in vitro biocompatibility and outperformed the commercial nano-
paste already on the market.

7. 55
Type Volume Packing Art. code EAN bar code
Syringe 0.5 cc Box of 1 unit 4913105 8718026120498
0.5 cc Box of 2 units 4913205 8718026120535
1.0 cc Box of 1 unit 4913110 8718026120504
1.0 cc Box of 2 units 4913210 8718026120542
2.0 cc Box of 1 unit 4913120 8718026120511
2.0 cc Box of 2 units 4913220 8718026120559
3.0 cc Box of 1 unit 4913130 8718026121884
3.0 cc Box of 2 units 4913230 8718026121891
5.0 cc Box of 1 unit 4913150 8718026120528
5.0 cc Box of 2 units 4913250 8712026120566
Ordering Information

8. 66
DBM The putty version of the ZETH DBM (demineralized bone matrix)
contains 80% demieralized human bone by volume and provides optimal
characteristics for guided bone regeneration. The crush version of the
ZETH DBM is a mix of 70% putty with 30% allograft cancellous crushed
bone chips (1-6mm). This will allow a rigid and solid filling of the bone void.
ZETH DBM is available in 1.0, 2.5, 5.0 and 10 cc. The DBM is also avail-
able in flexible strips; these will become flexible after hydration, The DBM
FLEX is available in three sizes; 15x15, 20x30 and 25x50mm.
Our safe standard enables rapid and reliable bone repair
ZETH DBM substitute
KYERON DBM is a ready-to-use injectable
and may be used in a variety of orthopaedic,
reconstructive, neurosurgical, and periodontal
tissue grafting procedures. KYERON DBM is
a powerful bone graft material which provides
superior handling characteristics
BONE CHIPS
The ZETH human tissue is also available
in cancellous and cortical-cancellous bone
chips of different granules sizes and convenient volumes. The smallest granules size is 0.5-2mm and the largest is
4-10mm and it is available from 1cc to 60 cc.
ZETH bone chips are completed under environmentally controlled conditions. All steps are rigorously quality con-
trolled. ZETH bone chips may be used in a variety of orthopaedic, reconstructive, neurosurgical, and periodontal
tissue grafting procedures.
The ZETH DBM products are processed by a four step production process by
acidification of allograft bone chips. The whole production procedure will remove
any cells and bacteria including DNA and RNA.This will ensure the ZETH DBM to
be acellular, Our production is completed under environmentally controlled condi-
tions. All steps are rigorously quality controlled.
KYERON and our tissue partners are accredited by the AATB and comply with the voluntary standards and guide-
lines developed by AATB. The source of human tissue for the ZETH products is USA, from an AATB approved
bone bank.
AATB ACCREDITATION

9. 77
Recovery of bone is conducted by highly trained procurement technicians in accordance with AATB standards.
Technicians complete an examiniation to identify possible physical evidence of any high risk conditions and tissue
recovery is performed within recommended time constraints. Aseptic techniques such as surgical skin prep and
sterile instruments are utilised to ensure a high quality tissue.
A blood sample is collected from the donor and tested for infectious diseases by a CLIA-certified laboratory. Sero-
logical testing includes:
- Antibody to Human Immunodeficiency Virus 1 & 2 (anti HIV 1 & 2)
- Hepatitis B Surface ANitgen (HBsAg)
- Hepatitis B Core IgG/IgM Antibody (HBcAb)
- Antibody to Hepatitis C (anti-HCV)
- Antibody to Human T-Cell Lymphotropic Virus Type I & II (anti-HLTV Type I & II)
- Rapid Plasma Reagin or Serologic Test for Syphilis (STS by RPR)
- Human Immunodeficiency Virus DNA using polymerase chain reaction (HIV NAT) using Transcription Mediated
Amplification (TMA)
Swab cultures for microbiological testing are obtained either at the time of recovery or prior to process-
ing. Cultures are incubated in two types of media at two temperatures for a minimum of seven days. Any
aerobic or anaerobic bacteria detected are identified to the genus level.
Our freeze dried ZETH (DBM and ALLOGRAFTS) products are sterilised by gamma irradiation.
Ordering Information
Type Volume Packing Art. code EAN bar code
DBM Putty / Paste 1.0 cc Pouch of 1 unit 4961110 8718026120825
(syringe) 2.5 cc Pouch of 1 units 4961120 8718026120832
5.0 cc Pouch of 1 unit 4961130 8718026120849
10.0 cc Pouch of 1 units 4961140 8718026120856
In accordance with AATB and FDA requirements, KYERON and its recovery partners utilise extensive evaluation
criteria to identify and exclude high risk donors. To ensure the safety of each allograft produced, all recovered
tissue is first quarantined until donor eligibility has been established Donor eligibility is assessed using a compre-
hensive screening process that includes a complete medical and social history, physical examination, serological
evaluation and microbiological testing.

10. 8

11. 99